In the preclinical studies reported herein, using co-administration of CA XII inhibitor with existing chemotherapies in Pgp+ve/CA XII+ve cancer models, typically, cells are treated with CA XII inhibitor at nanomolar concentrations and mice are dosed with CA XII inhibitor at μg/kg levels. The gene discussed is PGP; the disease is cancer.